.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,563,763

« Back to Dashboard

Claims for Patent: 7,563,763

Title:FSH and FSH variant formulations, products and methods
Abstract:This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
Inventor(s): Hoffmann; James Arthur (Greenwood, IN), Lu; Jirong (Indianapolis, IN)
Assignee: Ares Trading S.A. (Aubonne, CH)
Application Number:11/212,423
Patent Claims: 1. A method for administering follicle stimulating hormone (FSH), the method comprising: providing a pharmaceutical formulation comprising an aqueous diluent, human FSH, and a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof, said human FSH consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6, the alpha-subunit and beta-subunit held together by noncovalent interactions, said human FSH being present as the biologically-active, heterodimeric protein form of human FSH at a concentration of about 5.0 .mu.g/ml to about 200 .mu.g/ml, said preservative being present in said aqueous diluent in an effective anti-microbial amount; injecting a first portion of the pharmaceutical formulation into a human in need of ovarian follicle or testicular stimulation, said injecting a first portion providing an effective dose of biologically active human FSH for ovarian follicle or testicular stimulation in the human; injecting a second portion of the pharmaceutical formulation into said human twenty four hours or greater after said injecting a first portion, said injecting a second portion providing an effective dose of biologically active human FSH for ovarian follicle or testicular stimulation in the human, the formulation having a stability such that each of the first and second portions injected into the human contain a pharmaceutically-effective amount of FSH.

2. The method of claim 1 in which the preservative is benzyl alcohol.

3. The method of claim 1 in which the preservative is m-cresol.

4. The method of claim 1 in which said human FSH is present as the biologically-active, heterodimeric protein form of human FSH at a concentration of about 10 .mu.g/mL to about 200 .mu.g/mL.

5. The method of claim 1 in which the FSH is recombinant FSH.

6. The method of claim 5 in which the preservative is benzyl alcohol.

7. The method of claim 5 in which the preservative is m-cresol.

8. The method of claim 1 and which further includes administering one or more additional portions of the pharmaceutical formulation, the formulation having a stability such that each additional administered portion includes a pharmaceutically-effective amount of FSH for ovarian follicle or testicular stimulation in the patient.

9. The method of claim 8 in which said administering occurs over a period of several days.

10. The method of claim 9 in which said administering continues for a cycle of treatment of the patient.

11. A method for treating a patient, comprising: providing a pharmaceutical formulation comprising an aqueous diluent, a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof, and human FSH, said human FSH being present in said pharmaceutical formulation in a solubilized biologically-active, heterodimeric protein form consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6, the alpha-subunit and beta-subunit held together by noncovalent interactions, said human FSH being present in the biologically-active, heterodimeric protein form at a concentration of about 5.0 .mu.g/ml to 2 mg/ml, said preservative being present in said pharmaceutical formulation in an effective anti-microbial amount; holding the pharmaceutical formulation for twenty four hours or greater, the formulation having a stability such that it contains a pharmaceutically-effective amount of FSH after being held for twenty four hours or greater; and after said holding, administering by injection an amount of said pharmaceutical formulation to a human so as to provide an effective dose of human FSH for ovarian follicle or testicular stimulation in the human.

12. The method of claim 11 in which the preservative is benzyl alcohol.

13. The method of claim 11in which the preservative is m-cresol.

14. A method for administering a stable FSH formulation to a patient comprising: providing a first container containing freeze dried human FSH present in a biologically-active, heterodimeric protein form consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6, the alpha-subunit and beta-subunit held together by noncovalent interactions; providing a second container containing an aqueous solvent including a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof; combining the aqueous solvent and the freeze dried FSH to obtain a pharmaceutical formulation containing human FSH, the FSH being present in the formulation in a biologically-active, heterodimeric protein form consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6, the alpha-subunit and beta-subunit held together by noncovalent interactions, the human FSH being present in the biologically-active, heterodimeric protein form at a concentration of about 5.0 .mu.g/ml to about 200 .mu.g/ml, the preservative being present in the formulation in an effective anti-microbial amount, the formulation having a stability such that it contains a pharmaceutically-effective amount of FSH after being held for a period of twenty four hours or greater; and administering the pharmaceutical formulation by injection to a patient.

15. The method of claim 14 in which the preservative is benzyl alcohol.

16. The method of claim 14 in which the preservative is m-cresol.

17. An article of manufacture useful for preparing a stable FSH formulation for administration to a patient, comprising a kit including: a first container containing freeze dried human FSH present in a biologically-active, heterodimeric protein form consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6, the alpha-subunit and beta-subunit held together by noncovalent interactions; a second container containing an aqueous solvent including a preservative selected from the group consisting of benzyl alcohol, m-cresol and mixtures thereof, the second container including an amount of solvent sufficient to solubilize the freeze dried FSH in the first container to form a reconstituted formulation containing human FSH in a biologically-active, heterodimeric protein form consisting of an alpha-subunit having SEQ ID NO:5 and a beta-subunit having SEQ ID NO:6 with the alpha-subunit and beta-subunit held together by noncovalent interactions, the amount of solvent farther being sufficient to form a reconstituted formulation with the freeze dried FSH in the first container in which the human FSH is present in the biologically-active, heterodimeric protein form at a concentration of about 5.0 .mu.g/ml to about 200 .mu.g/ml, the preservative being present in the solvent in an amount sufficient to provide an effective anti-microbial amount for the reconstituted formulation, the reconstituted formulation having a stability such that it contains a pharmaceutically-effective amount of FSH after being held for a period of twenty four hours or greater.

18. The article of claim 17 in which the preservative is benzyl alcohol.

19. The article of claim 17 in which the preservative is m-cresol.

20. The article of claim 17 in which the preservative is a mixture of benzyl alcohol and m-cresol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc